Neogenomics (NEO) EBIAT (2016 - 2025)
Historic EBIAT for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$9.9 million.
- Neogenomics' EBIAT rose 3551.94% to -$9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$108.0 million, marking a year-over-year decrease of 3721.64%. This contributed to the annual value of -$108.0 million for FY2025, which is 3721.64% down from last year.
- Per Neogenomics' latest filing, its EBIAT stood at -$9.9 million for Q4 2025, which was up 3551.94% from -$27.1 million recorded in Q3 2025.
- In the past 5 years, Neogenomics' EBIAT registered a high of $75.9 million during Q2 2021, and its lowest value of -$49.4 million during Q1 2022.
- For the 5-year period, Neogenomics' EBIAT averaged around -$21.4 million, with its median value being -$23.5 million (2022).
- Within the past 5 years, the most significant YoY rise in Neogenomics' EBIAT was 121185.52% (2021), while the steepest drop was 89577.63% (2021).
- Neogenomics' EBIAT (Quarter) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then skyrocketed by 35.52% to -$9.9 million in 2025.
- Its EBIAT was -$9.9 million in Q4 2025, compared to -$27.1 million in Q3 2025 and -$45.1 million in Q2 2025.